Bobbio Antonio, Caporale Domenico, Internullo Eveline, Ampollini Luca, Bettati Stefano, Rossini Elisabetta, Carbognani Paolo, Rusca Michele
Department of Surgical Science, Unit of Thoracic Surgery, University of Parma, Parma, Italy.
Eur J Cardiothorac Surg. 2007 Jan;31(1):70-4. doi: 10.1016/j.ejcts.2006.10.020. Epub 2006 Nov 20.
Atrial fibrillation (AF) is a common complication after thoracic surgery. The objective of the study was to prospectively evaluate the postoperative outcome of patients undergoing lung resection and presenting with new onset of AF. The postoperative course of AF was also evaluated in relation to either amiodarone or diltiazem employed as anti-arrhythmic agents.
A prospective observational study during a 3-year period was designed to evaluate all patients presenting AF as a complication of anatomic lung resections. The absence of a history of heart rhythm disease was an inclusion criterion. Amiodarone was employed as the anti-arrhythmic drug during the first 18 months, and diltiazem in the second half of the study. Anti-arrhythmic drugs were started intravenously; when rhythm was restored or after 48h of treatment, they were administered orally. AF duration, recurrences and the postoperative outcome of patients were recorded.
Thirty patients fulfilled inclusion criteria. No deaths occurred; median hospital stay was 10 days (range 6-37). AF presented as a solitary complication in 17 patients; in 10 patients it was associated with a respiratory complication and in the last three patients in one case each with pulmonary embolism, acute renal failure and chylothorax respectively. AF occurred on median post-operative day 2 (range: 1-9). Sinus rhythm restoration within the first 24h was observed in 11 (70%) out of the 15 patients receiving diltiazem and in 10 (67%) out of the 15 receiving amiodarone. After 48h, in 80% of patients in both groups cardioversion was achieved. AF recurrence occurred in 11 patients (37%). In 10 out of these 11 patients iterative intravenous treatment was attempted and in all a permanent cardioversion was achieved. Fisher's exact test indicated AF recurrence as being significantly correlated to the presence of a respiratory complication (p=0.02).
Postoperative outcome of patients undergoing lung surgery with new onset of AF resulted as being significantly complicated by AF recurrence in the case of an associated respiratory complication. The pharmacological strategies tested during this pilot study led to no differences in the postoperative course of AF.
心房颤动(AF)是胸外科手术后常见的并发症。本研究的目的是前瞻性评估接受肺切除手术且新发房颤患者的术后结局。还针对用作抗心律失常药物的胺碘酮或地尔硫䓬评估了房颤的术后病程。
设计了一项为期3年的前瞻性观察性研究,以评估所有因解剖性肺切除并发症而出现房颤的患者。纳入标准为无心律失常病史。在研究的前18个月使用胺碘酮作为抗心律失常药物,在后半段使用地尔硫䓬。抗心律失常药物开始静脉给药;心律恢复后或治疗48小时后,改为口服给药。记录房颤持续时间、复发情况及患者的术后结局。
30例患者符合纳入标准。无死亡病例;中位住院时间为10天(范围6 - 37天)。17例患者房颤为单独并发症;10例患者与呼吸并发症相关,最后3例患者分别合并肺栓塞、急性肾衰竭和乳糜胸各1例。房颤发生的中位术后天数为2天(范围:1 - 9天)。接受地尔硫䓬治疗的15例患者中有11例(70%)在术后24小时内恢复窦性心律,接受胺碘酮治疗的15例患者中有10例(67%)恢复窦性心律。48小时后,两组80%的患者实现了心律转复。11例患者(37%)发生房颤复发。在这11例患者中的10例尝试了反复静脉治疗,均实现了永久性心律转复。Fisher精确检验表明房颤复发与呼吸并发症的存在显著相关(p = 0.02)。
新发房颤的肺手术患者术后结局因合并呼吸并发症时房颤复发而显著复杂化。本初步研究中测试的药物治疗策略在房颤术后病程方面未导致差异。